Oxytocin peptide analogue
Carbetocin
Carbetocin is a synthetic oxytocin analogue. Its molecular research shows that sharing a receptor does not mean reproducing every signaling pathway or the same receptor trafficking. The ingredient must also be distinguished from any formulated presentation.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
Receptor, selectivity and context
Record the receptor panel actually measured. Absence of a result for another receptor does not establish absence of activity.
- Which receptor subtype and species were evaluated?
- Was affinity, functional potency or an integrated response measured?
- Does the comparison include the alternative receptors needed for a selectivity claim?
Mechanism described in the literature
In cellular assays with human receptors, carbetocin showed partial agonism of OXTR–Gq coupling without reproducing oxytocin's complete profile. The same system showed receptor internalization without beta-arrestin recruitment and without detectable recycling to the membrane.
Other names in the literature
- Carbetocin
The measured pathway changes the description
The 2016 publication used biosensors to compare OXTR with V1a and V1b receptors. Carbetocin did not activate the latter in the reported in vitro assays, although the authors proposed possible antagonism. Lack of activation in one readout is not the same as lack of recognition and does not prove exclusivity in every tissue.
Receptors also follow a cellular route
Internalization and recycling are different stages. The carbetocin findings prevent both from being summarized simply as temporary receptor disappearance. Whether the receptor returns to the surface matters when interpreting successive exposures, but this in vitro observation alone does not establish response duration in an organism.
A behavioral comparison with defined limits
In a 2025 Wistar-rat study, carbetocin changed the early nociceptive response in the formalin model in males, while atosiban showed a different temporal pattern. Pharmacological controls supported involvement of different pathways. Species, sex and outcome remain essential: the finding is not a general ranking of the compounds or a conclusion about human pain.
Questions and answers
Is carbetocin simply oxytocin with all its effects prolonged?
That description is incomplete. Cellular assays documented differences in signaling and receptor trafficking.
Does internalization imply recycling?
No. The carbetocin study measured both stages and found different behavior in vitro.
Sources
- Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation. — J Neuroendocrinol, 2016
- Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation.
- The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats. — Neuropharmacology, 2025
- The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats.